RT Journal Article
SR Electronic
T1 Multi-chain Fudan-CCDC model for COVID-19 in Iran
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.22.20075630
DO 10.1101/2020.04.22.20075630
A1 Pan, Hanshuang
A1 Shao, Nian
A1 Yan, Yue
A1 Luo, Xinyue
A1 Ahmadi, Ali
A1 Fadaei, Yasin
A1 Cheng, Jin
A1 Chen, Wenbin
YR 2020
UL http://medrxiv.org/content/early/2020/04/30/2020.04.22.20075630.abstract
AB Background COVID-19 has been deeply affecting people’s lives all over the world. It is significant for prevention and control to model the evolution effectively and efficiently.Methods We first propose the multi-chain Fudan-CCDC model which is based on the original Fudan-CCDC model to describe the revival of COVID-19 in some countries. Multi-chains are considered as the superposition of distinctive single chains. Parameter identification is carried out by minimizing the penalty function.Results From results of numerical simulations, the multi-chain model performs well on data fitting and reasonably interprets the revival phenomena. The band of ±25% fluctuation of simulation results could contain most seemly unsteady increments.Conclusion The multi-chain model has better performance on data fitting in revival situations compared with the single-chain model. It is predicted by the three-chain model with data by Apr 21 that the epidemic curve of Iran would level off on round May 10, and the final cumulative confirmed cases would be around 88820. The upper bound of the 95% confidence interval would be around 96000.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWenbin Chen is supported by the National Science Foundation of China (11671098, 91630309). Jin Cheng is supported in part by the National Science Foundation of China (11971121).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data employed in this paper are acquired from the World Health Organization (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports). All the data can be accessed publicly. No other data are used in this paper. https://www.who.in